Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
The FDA approved Novo Nordisk’s weight-loss drug Wegovy earlier this year to reduce the risk of major cardiovascular deaths in people with heart disease.
- Simplified Text
-
FDA approved Novo Nordisk's Wegovy to reduce risk of major cardiovascular deaths in people with heart disease
- Confidence Score
- 0.950
- Claim Maker
- The author
- Context Type
- News Article
- Context Details
-
{ "drug": "Wegovy", "event": "Reduce risk of major cardiovascular deaths", "organization": "FDA" } - Subject Tags
- UUID
- a1165f6b-cf00-4b35-8d72-78d4eca3eb47
- Vector Index
- ✗ No vector
- Created
- February 15, 2026 at 4:57 PM (2 months ago)
- Last Updated
- February 15, 2026 at 4:57 PM (2 months ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
Completed
News
21
claims
🔥
2 months ago
https://www.politico.com/newsletters/politico-pulse/2024/04/24/pharma-lobbying-up-in-2024-00153996
Pharmaceutical companies increased lobbying spending in the first quarter of 2024. Key issues driving the spending include 340B program reform, supply chain issues, and pharmacy benefit manager regulations. The article also covers Supreme Court arguments on abortion and bird flu fragments in milk.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.